BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27163538)

  • 21. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Belatacept: a new biologic and its role in kidney transplantation.
    Su VC; Harrison J; Rogers C; Ensom MH
    Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation.
    Barraclough KA; Staatz CE; Isbel NM; McTaggart SJ
    Nephrology (Carlton); 2010 Aug; 15(5):522-32. PubMed ID: 20649871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
    Kuypers DR
    Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
    [No Abstract]   [Full Text] [Related]  

  • 27. Belatacept utilization recommendations: an expert position.
    Grinyó JM; Budde K; Citterio F; Charpentier B
    Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological agents in kidney transplantation: belatacept is entering the field.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
    Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
    Trials; 2014 Dec; 15():489. PubMed ID: 25494823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor Inhibitor Sunitinib Prevents Chronic Allograft Injury in Experimental Kidney Transplantation Model.
    Rintala JM; Savikko J; Palin N; Rintala SE; Koskinen PK; von Willebrand E
    Transplantation; 2016 Jan; 100(1):103-10. PubMed ID: 26262503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in immunosuppressive therapy for prevention of renal allograft rejection.
    Lunsford KE; Barbas AS; Brennan TV
    Curr Opin Organ Transplant; 2011 Aug; 16(4):390-7. PubMed ID: 21666473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
    West K
    Curr Opin Investig Drugs; 2009 May; 10(5):491-504. PubMed ID: 19431082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active management versus minimization of immunosuppressives of BK virus-associated nephropathy after a kidney transplant.
    Halim MA; Al-Otaibi T; Gheith O; Zkaria Z; Mosaad A; Said T; Nair P; Nampoory N
    Exp Clin Transplant; 2014 Dec; 12(6):528-33. PubMed ID: 25489803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-regulatory cells in chronic rejection versus stable grafts.
    Al-Wedaie F; Farid E; Tabbara K; El-Agroudy AE; Al-Ghareeb SM
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():170-6. PubMed ID: 25894149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
    van Gelder T; Silva HT; de Fijter JW; Budde K; Kuypers D; Tyden G; Lohmus A; Sommerer C; Hartmann A; Le Meur Y; Oellerich M; Holt DW; Tönshoff B; Keown P; Campbell S; Mamelok RD
    Transplantation; 2008 Oct; 86(8):1043-51. PubMed ID: 18946341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK3 inhibitor-based immunosuppression in allogeneic islet transplantation in cynomolgus monkeys.
    Kim JM; Shin JS; Min BH; Kang SJ; Yoon IH; Chung H; Kim J; Hwang ES; Ha J; Park CG
    Islets; 2019; 11(5):119-128. PubMed ID: 31483188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.